RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Testing selnoflast early in Parkinson's

This early study compares an experimental medicine with placebo and investigates safety and effects in the body.

Testing a treatment or activity · Study reference: NL-OMON54457

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported date)
2022-09-14

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 18 to 99 · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: Not reported

Inclusion criteria: *Age 40-85 years *Diagnosis of clinically probable idiopathic PD based on MDS criteria with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity) *A time from diagnosis of PD of at least 3 to maximum 60 months at screening Other inclusion criteria can be found in protocol section 5.1 Exclusion criteria: *Medical history indicating a Parkinsonian syndrome other than idiopathic PD *History of brain surgery for PD. *Known carriers for mutations in the following genes: alpha-synuclein, LRRK2, GBA, PRKN, PINK1, or DJ1. *Diagnosis of dementia or another significant central nervous system (CNS) disease other than PD; history of repeated clinically significant head injury as judged by the Investigator; history of epilepsy or seizure disorder other than febrile seizures as a child. Other inclusion criteria can be found in protocol section 5.2
Full study name & original research details

Official study title

A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON*S DISEASE - BP43176 IZD334

Short title used by the registry

A PHASE 1B, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON*S DISEASE

Original description

Intervention: A minimum of 48 eligible participants will be randomized to either receive selnoflast 200 mg BID or placebo in a double-blind manner in a ratio active/placebo of 2:1. Treatment duration will be approximately 28 days for all participants. After the last dose of selnoflast or placebo, all participants will enter a safety follow-up period for 14 days. Primary outcome: To evaluate the safety and tolerability of selnoflast compared to placebo. Secondary outcome: To investigate the pharmacokinetics of selnoflast (and metabolites, as appropriate) in plasma. To evaluate the effect of selnoflast on neuroinflammation in brain areas as measured by TSPO-PET [18F]-DPA-714 imaging binding.

Conditions reported: EARLY IDIOPATHIC PARKINSONS DISEASE Parkinson's disease;10029305

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
A minimum of 48 eligible participants will be randomized to either receive selnoflast 200 mg BID or placebo in a double-blind manner in a ratio active/placebo of 2:1. Treatment duration will be approximately 28 days for all participants. After the last dose of selnoflast or placebo, all participants will enter a safety follow-up period for 14 days.
Phases
Not reported
Sponsor
Roche Nederland B.V.
Start date reported by registry
2022-09-14 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Netherlands

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.